PARP inhibitors in prostate cancer. Part 2
Thanks to novel approaches and genomic stratification we have entered a new era where advanced genitourinary cancers can achieve cure and long-term survival without disease progression, but there are still many challenges to be addressed before using personalized medicine into daily uro-oncological practice.
|Organiser||European School of Urology (ESU)|
Around 20% of patients with advanced prostate cancer present germline or tumour mutations in HRR-related genes, the most common being BRCA2. The recent approvals of PARP inhibitors represent the first molecular guided pharmaceutical agents for men with prostate cancer. This webinar series aims to highlight the recent developments on PARP inhibitors in prostate cancer.
Contact our organiser
European School of Urology (ESU)